BioCentury
ARTICLE | Clinical News

Neuro-Hitech falls on AD data

February 2, 2008 2:01 AM UTC

Neuro-Hitech (NASDAQ:NHPI) fell $1.99 (68%) to $0.93 on Friday after Huperzine A missed the primary endpoint of a significant improvement in ADAS-Cog scores for the low-dose group (200 ug twice daily)...